Medically reviewed by Sharif Alijla, MD. Last reviewed July 2026.
Two beliefs stop most people from considering a cancer clinical trial, and both are wrong. Trials are not a last resort, since many are for newly diagnosed patients and some are for people without cancer at all. And you will not be given a placebo instead of treatment: where an effective treatment exists, everyone gets it, and the placebo substitutes only for the unproven drug being tested. About 7.1% of US adult cancer patients join a treatment trial, and the main reason is not that patients refuse. It is that 56% have no trial available where they are treated, and when a trial is offered, around 55% say yes. Here is how trials actually work.
What the Phases Mean
| Phase | What it tests | Typical size |
|---|---|---|
| Phase 1 | Safety, tolerable dose, side effects | 15 to 30 |
| Phase 2 | Whether it works against the cancer | 50 to 100 |
| Phase 3 | Comparison against current standard treatment | 100 to several thousand |
| Phase 4 | Long-term safety after approval | Varies |
Combined phase 1/2 and phase 2/3 designs are now common, which speeds things up.
On phase 1 specifically. The old picture of phase 1 as a pure toxicity screen for people out of options is outdated in oncology. Many modern phase 1 trials test targeted drugs in patients selected by a specific tumour marker, and response rates can be meaningful. Participants receive protocol-defined care with independent ethics board and safety monitoring board oversight. The FDA has issued specific guidance on enrolling patients who still have other treatment available, which is precisely how trials moved earlier in the treatment pathway.
The Placebo Question
This is the single biggest fear people have, so it is worth being precise.
Nobody is given a placebo instead of effective treatment when effective treatment exists. That would be unethical and it is not how cancer trials are designed.
The standard design is add-on: everyone receives the current standard treatment, and on top of that one group receives the investigational drug while the other receives a placebo. The placebo replaces only the drug whose value is unknown.
Placebo alone is used only where there is no known effective treatment for that cancer at that stage, which is a narrow situation.
Blinding is used because it protects the result. When outcomes are judged by scan interpretation or symptom scores, knowing which treatment someone received can influence the assessment.
Whatever the design, placebo use is always disclosed in the consent form before you enrol. If you are unsure, ask directly whether the trial uses one and what each arm receives.
Why So Few People Take Part
The 7.1% figure supersedes the older 3% to 5% often quoted. If you count all research types including tissue banking and registries, about 21.9% of patients take part in something.
The reasons are mostly structural rather than attitudinal. Over 77% of non-enrolment comes down to structural or clinical factors. Around 56% of patients had no trial available at their institution, and about 22% were ineligible for the one that existed.
Where you are treated matters enormously:
| Setting | Treatment trial enrolment |
|---|---|
| NCI-designated comprehensive cancer centre | 21.6% |
| Academic centre, not NCI-designated | 5.4% |
| Integrated network | 5.7% |
| Community programme | 4.1% |
The practical implication is that if trials interest you, ask specifically whether one is available and whether referral to a larger centre is worth considering. Many patients are simply never asked.
Who Pays
Costs split into two categories, and understanding this prevents unpleasant surprises.
Routine patient costs are the care you would have received anyway: scans, blood tests, clinic visits, standard drugs, and managing complications. These are billed to your insurance.
Research costs are the investigational drug itself and any test or visit that exists only to collect research data. The trial sponsor pays these.
Coverage of routine costs is now required across all three major payers:
Private insurance. Since January 2014, non-grandfathered plans must cover routine patient costs for qualifying trials in cancer and other life-threatening conditions, and cannot drop you or discriminate for participating.
Medicare. Covers routine costs of qualifying trials plus treatment of complications. Medicare Advantage plans must cover qualifying trials regardless of network and cannot require prior authorisation.
Medicaid. Since 1 January 2022, covering routine costs of qualifying trials is a mandatory Medicaid benefit that states cannot opt out of. This is recent and not widely known.
The gaps to watch: grandfathered health plans, out-of-network trial sites, and travel, lodging, and childcare, which are generally not covered by any of the above. Ask the trial coordinator what support exists, since some trials reimburse travel.
Eligibility Is Broadening
Trial eligibility criteria were historically far narrower than they needed to be, excluding people who could have safely participated.
Joint recommendations from ASCO and Friends of Cancer Research have pushed to relax criteria around washout periods, other medications, prior treatments, laboratory thresholds, and performance status. Modelling suggests that relaxing just three criteria, on kidney function, brain metastases, and previous cancers, would nearly double the eligible population for lung cancer trials.
If you were told you are ineligible for a trial, it is worth asking whether that is still accurate, and whether other trials have broader criteria.
Who Is Missing From Trials
Representation in the trials that support FDA cancer drug approvals is poor, and it has not improved much.
Measured against how often these groups develop cancer, Black patients enrol at roughly a quarter of the expected rate, Hispanic patients at about half, and people aged 65 and over at about two-thirds. Analysis across time found no significant improvement, and representation of older adults slightly declined.
This matters clinically, not just as a fairness question. Drugs are approved on the basis of who was studied, and older patients in particular are the ones most likely to receive them afterwards.
How to Find a Trial
NCI Clinical Trials Search is the best starting point for cancer specifically, since it is curated rather than exhaustive. ClinicalTrials.gov lists every registered trial and is more comprehensive but harder to filter.
Use the free human help. The NCI Cancer Information Service at 1-800-4-CANCER has specialists who will run a tailored trial search for your situation, Monday to Friday. This is a genuinely underused service and costs nothing.
CancerCare and the Cancer Support Community also provide navigation help.
Ask your oncologist directly: “Is there a clinical trial I should consider, here or anywhere else?” Given that 56% of patients have no trial available locally, the answer may involve a referral.
Your Rights
You must give written informed consent before anything happens. The consent form must set out the purpose, the procedures, the risks, the alternatives including standard treatment outside the trial, and whether a placebo is used. Consent is ongoing, so you must be told about new risk information as it emerges.
You can leave a trial at any time, for any reason, without penalty and without losing your usual care. You do not need to justify the decision.
Will a Trial Help Me Live Longer?
An honest answer, since this is often oversold.
There is a widespread belief in a “trial effect,” where participants do better simply by taking part. The evidence for it is weak. A review comparing trial participants with non-participants found that 71.7% of comparisons showed no significant difference, 18.7% favoured participation, and 9.5% favoured non-participation.
Where participants appear to do better, it is largely explained by selection. Trial participants tend to be younger, fitter, and treated at higher-volume centres.
The defensible statement: there is no evidence that trial participants do worse, and trials offer access to treatments not otherwise available plus unusually close monitoring. But joining a trial should not be presented as a survival strategy in itself. It is a reasonable option to consider, weighed against the specific trial and your own situation.
Cancer Clinical Trial FAQs
Will I get a placebo instead of treatment?
No. Where effective treatment exists, everyone in the trial receives it. The placebo replaces only the unproven drug being tested. Placebo alone is used only where no effective treatment exists, and any placebo use is disclosed in the consent form.
Are clinical trials only for people who have run out of options?
No. Trials exist at every stage, including for newly diagnosed patients, and some are prevention or screening trials for people without cancer.
Who pays for a clinical trial?
Your insurance covers routine care costs, which private plans, Medicare, and Medicaid are all now required to do for qualifying trials. The sponsor pays for the investigational drug and research-only testing. Travel and lodging are usually not covered, so ask what support exists.
How do I find a cancer clinical trial?
Start with the NCI Clinical Trials Search, or call the NCI Cancer Information Service at 1-800-4-CANCER, where specialists will search for you at no cost. Also ask your oncologist whether a referral elsewhere is worth considering.
Can I leave a trial once I have started?
Yes, at any time and for any reason, without penalty and without affecting your regular care. You do not need to give a reason.
Do people in trials live longer?
The evidence does not support a general survival benefit from participating. Most comparisons find no significant difference, and apparent advantages largely reflect participants being healthier to begin with. Trials do provide access to otherwise unavailable treatments and close monitoring.
